Status:
COMPLETED
A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This study will investigate the safety and efficacy of an investigational drug, PF-04171327 on the signs and symptoms of rheumatoid arthritis in patients that require glucocorticoids while on backgrou...
Eligibility Criteria
Inclusion
- Patients ≥ 18 years of age, diagnosed with rheumatoid arthritis for a minimum duration of 3 months
- On stable dose of methotrexate for at least 6 weeks prior to screening
- Patient must have minimum disease activity level of ≥ 6 tender/painful joints, ≥ 6 swollen joints and CRP ≥ 0.7 mg/dL
- Not currently receiving steroid medication
Exclusion
- Pregnant or nursing women
- Patients that have active infections, TB, HIV and/or Hepatitis B or C
- Patients that have a history of intolerance or significant adverse effects with the use of glucocorticoids
Key Trial Info
Start Date :
October 7 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 29 2010
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT00938587
Start Date
October 7 2009
End Date
July 29 2010
Last Update
November 22 2023
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Anniston Medical Clinic, PC
Anniston, Alabama, United States, 36207
2
Pinnacle Research Group, LLC
Anniston, Alabama, United States, 36207
3
Allergy, Asthma, Arthritis and Lung
Daytona Beach, Florida, United States, 32114
4
Elite Research Institute
Miami, Florida, United States, 33169